Clinical trial
Extension Study Evaluating Etanercept in Ankylosing Spondylitis
NCT00410046 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00410046 |
|---|---|
| Title | Extension Study Evaluating Etanercept in Ankylosing Spondylitis |
| Official title | An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Ankylosing Spondylitis |
| Intervention type | Drug |
| Interventions | Enbrel (etanercept) |
| Enrollment | 84 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Dec 12, 2006 |
| Last update posted | May 11, 2012 |
| Countries | Denmark, Finland, Sweden, United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: